At present, the only SERMs routinely used in clinical practice are tamoxifen and raloxifene. Tamoxifen is used essentially as adjuvant treatment in women with breast cancer. Its use is related to estrogenic effects on the uterus. Specifically, tamoxifen can be associated with an increase not only in endometrial hyperplasia and cancer risk but also in uterine leiomyoma dimensions and in a risk of developing active endometriotic lesions. Raloxifene is actually used for the treatment and prevention of post-menopausal osteoporosis. Also, if raloxifene has been shown to have any effect on uterine leiomyomas in vitro and in animal models, to date no concrete efficacy has been demonstrated in normally cycled premenopausal women. Moreover, the addition of raloxifene to GnRH-a administration can be useful for limiting GnRH-a-related side effects and increasing the rate of reduction in tumor size. Regarding the use of SERMs in women with endometriosis, the efficacy of raloxifene or other compounds is only potential. Experimental studies to determine if SERMs have a greater potency against uterine leiomyomas and endometriosis are currently in progress.
|Title of host publication||Selective Estrogen Receptor Modulators: A New Brand of Multitarget Drugs|
|Publisher||Springer Berlin Heidelberg|
|Number of pages||21|
|ISBN (Print)||3540242279, 9783540242277|
|Publication status||Published - 2006|
ASJC Scopus subject areas